FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308514093> ?p ?o ?g. }

• W4308514093 endingPage "20" @default.
• W4308514093 startingPage "1" @default.
• W4308514093 abstract "Dexmedetomidine is an alpha-2 adrenoceptor agonist which is widely used for sedation. Dexmedetomidine does not suppress the respiratory drive and produces a state of cooperative sedation; it may be associated with beneficial outcomes in the general critical care population. The role of dexmedetomidine in the treatment of toxicologic conditions (excluding alcohol withdrawal) is unclear.To critically assess and summarize the literature regarding the use of dexmedetomidine in toxicologic conditions other than alcohol withdrawal.We performed a systematic review of the medical literature to identify all existing evidence regarding the use of dexmedetomidine for toxicologic conditions. We excluded reviews and commentary, studies reporting exclusively on alcohol withdrawal, and studies reporting the use of dexmedetomidine to treat iatrogenic sedative withdrawal in the intensive care unit. We also performed a review of the Toxicology Investigators Consortium (ToxIC) database for patients treated with dexmedetomidine.We identified 98 studies meeting inclusion criteria; 87 of these were case reports or case series, representing 99 unique cases. Eleven articles with other designs were identified, which included 138 patients treated with dexmedetomidine for toxicologic conditions. Ninety-three cases from the ToxIC registry met inclusion criteria. Common indications for dexmedetomidine included stimulant intoxication, sedative withdrawal, serotonin syndrome, antimuscarinic toxidrome, opioid withdrawal, and cannabinoid intoxication. Dexmedetomidine was usually administered by continuous infusion; bolus administration was reported in a minority of cases. Adverse effects were uncommon. The quality of evidence was generally low, given the preponderance of case reports, the rate of missing or poorly reported data, and the near-universal co-administration of other sedatives.Fifty-nine patients with stimulant poisoning were treated with dexmedetomidine. There was reasonably good evidence that dexmedetomidine was helpful in the treatment of stimulant poisoning.Twenty-two patients with sedative withdrawal were treated with dexmedetomidine. Several case reports of very high-quality suggested efficacy of dexmedetomidine for this indication, particularly for baclofen withdrawal.Twenty-six patients with serotonin syndrome were treated with dexmedetomidine. This evidence was of lower quality due to missing clinical details, potential overdiagnosis of serotonin syndrome, and near-universal concomitant treatment with other sedatives.Forty-two patients with antimuscarinic poisoning were treated with dexmedetomidine. This evidence was of low quality and was limited by infrequent use of the preferred antidote, physostigmine.Forty-four patients with opioid withdrawal were treated with dexmedetomidine. This evidence was of low quality due to missing clinical details and near-universal concomitant treatment with other agents. The one high-quality trial reported the use of dexmedetomidine in ultra-rapid opioid detoxification, which is not indicated in modern practice.Five patients with cannabinoid intoxication were treated with dexmedetomidine. No definite conclusion can be drawn from the limited available evidence.It is important to distinguish between the use of dexmedetomidine as a general sedative, which is likely to increase as the overall utilization of dexmedetomidine in critical care settings increases, and the use of dexmedetomidine as a specific pharmacologic treatment for a toxicologic condition. Well-established pharmacologic data from animal and human studies suggest dexmedetomidine counteracts stimulant-induced norepinephrine release. The mechanism by which dexmedetomidine treats sedative withdrawal is unclear. Some animal data show that dexmedetomidine may indirectly suppress serotonin release, which may suggest a role for dexmedetomidine in this condition.There is a small and generally low-quality body of evidence which suggests that dexmedetomidine may be helpful in the treatment of certain toxicologic conditions, particularly stimulant intoxication and sedative withdrawal. Further high-quality research is needed to clarify the role of dexmedetomidine in patients with toxicologic conditions." @default.
• W4308514093 created "2022-11-12" @default.
• W4308514093 creator A5000698884 @default.
• W4308514093 creator A5016165920 @default.
• W4308514093 creator A5065499809 @default.
• W4308514093 date "2022-11-08" @default.
• W4308514093 modified "2023-09-24" @default.
• W4308514093 title "Dexmedetomidine in the treatment of toxicologic conditions: a systematic review and review of the toxicology investigators consortium database" @default.
• W4308514093 cites W1515279996 @default.
• W4308514093 cites W1821418478 @default.
• W4308514093 cites W1972649294 @default.
• W4308514093 cites W1993435783 @default.
• W4308514093 cites W2000431779 @default.
• W4308514093 cites W2002516971 @default.
• W4308514093 cites W2026068578 @default.
• W4308514093 cites W2038474785 @default.
• W4308514093 cites W2038848560 @default.
• W4308514093 cites W2048272107 @default.
• W4308514093 cites W2048999525 @default.
• W4308514093 cites W2062295106 @default.
• W4308514093 cites W2062817404 @default.
• W4308514093 cites W2064789095 @default.
• W4308514093 cites W2066730651 @default.
• W4308514093 cites W2069044170 @default.
• W4308514093 cites W2072564314 @default.
• W4308514093 cites W2072878237 @default.
• W4308514093 cites W2076713549 @default.
• W4308514093 cites W2082311304 @default.
• W4308514093 cites W2083886307 @default.
• W4308514093 cites W2088781889 @default.
• W4308514093 cites W2090252372 @default.
• W4308514093 cites W2093719422 @default.
• W4308514093 cites W2096305131 @default.
• W4308514093 cites W2101582841 @default.
• W4308514093 cites W2103698538 @default.
• W4308514093 cites W2123778879 @default.
• W4308514093 cites W2124712827 @default.
• W4308514093 cites W2127546477 @default.
• W4308514093 cites W2133052062 @default.
• W4308514093 cites W2135672238 @default.
• W4308514093 cites W2138055379 @default.
• W4308514093 cites W2158290224 @default.
• W4308514093 cites W2166324543 @default.
• W4308514093 cites W2166453373 @default.
• W4308514093 cites W2212219968 @default.
• W4308514093 cites W2321250409 @default.
• W4308514093 cites W2338480168 @default.
• W4308514093 cites W2412992442 @default.
• W4308514093 cites W2440750177 @default.
• W4308514093 cites W2482305477 @default.
• W4308514093 cites W2510306547 @default.
• W4308514093 cites W2511521367 @default.
• W4308514093 cites W2520152522 @default.
• W4308514093 cites W2531325770 @default.
• W4308514093 cites W2536846264 @default.
• W4308514093 cites W2552219293 @default.
• W4308514093 cites W2566915056 @default.
• W4308514093 cites W2576234460 @default.
• W4308514093 cites W2594574280 @default.
• W4308514093 cites W2598942517 @default.
• W4308514093 cites W2600981364 @default.
• W4308514093 cites W2608710237 @default.
• W4308514093 cites W2766153516 @default.
• W4308514093 cites W2793292948 @default.
• W4308514093 cites W2802397463 @default.
• W4308514093 cites W2810509521 @default.
• W4308514093 cites W2855735620 @default.
• W4308514093 cites W2905162655 @default.
• W4308514093 cites W2909065979 @default.
• W4308514093 cites W2910663243 @default.
• W4308514093 cites W2914928106 @default.
• W4308514093 cites W2932185501 @default.
• W4308514093 cites W2937331254 @default.
• W4308514093 cites W2950294084 @default.
• W4308514093 cites W2977317154 @default.
• W4308514093 cites W3000058348 @default.
• W4308514093 cites W3024726158 @default.
• W4308514093 cites W3036769662 @default.
• W4308514093 cites W3085905908 @default.
• W4308514093 cites W3092659890 @default.
• W4308514093 cites W3096232543 @default.
• W4308514093 cites W3108125760 @default.
• W4308514093 cites W3118615836 @default.
• W4308514093 cites W3120718391 @default.
• W4308514093 cites W3125824553 @default.
• W4308514093 cites W3143926195 @default.
• W4308514093 cites W3197126388 @default.
• W4308514093 cites W3199112989 @default.
• W4308514093 cites W3216701539 @default.
• W4308514093 cites W3216934001 @default.
• W4308514093 cites W4242670835 @default.
• W4308514093 cites W4289325137 @default.
• W4308514093 cites W2736059627 @default.
• W4308514093 doi "https://doi.org/10.1080/15563650.2022.2138761" @default.
• W4308514093 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36346349" @default.
• W4308514093 hasPublicationYear "2022" @default.
• W4308514093 type Work @default.
• W4308514093 citedByCount "0" @default.

• next